FDA fast-tracks VS-7375, an oral KRAS G12D inhibitor, opening new hope for pretreated advanced NSCLC and fueling pivotal ...

ASCO 2026 data link chronic-stress allostatic load to higher early-onset cancer risk, suggesting new tools for screening beyond genetics.

Natco Pharma and Lupin gained FDA approval for bioequivalent generic eribulin mesylate injection, potentially reducing ...

CYP2D6 poor metabolizers had ~5-fold higher payload exposure and excess grade ≥3 mucositis, neutropenia, febrile neutropenia, ...

Iza-bren is a potentially first-in-class bispecific ADC designed to target both EGFR and HER3. It features high affinity for ...

ASCO 2026 insights on 177Lu-PSMA-617 in mHSPC: safety, marrow and kidney monitoring, and what long-term MDS/AML risks may ...

Dr McDonald shares promising data linking GLP-1 use to lower breast cancer risk, highlighting the need for clinical trials to ...

Andrew L. Pecora, MD, discusses the significance of the long-term findings from the KEYNOTE-942 trial of intismeran autogene ...

Abemaciclib (Verzenio) reduced the risk of progression or death by 62% compared with placebo in patients with advanced ...

ASCO 2026: PSMAddition shows 177Lu-PSMA-617 boosts rPFS across mHSPC subgroups, with steady safety and insights on PSMA PET ...

Daniel Olson, MD, discusses the results of a phase 1 trial of brenetasfusp, a PRAME ImmTAC therapy in advanced melanoma.

The IGNYTE continues to show promising outcomes despite negative FDA decisions.